Gain Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GANX Nasdaq 2836 gaintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gain Therapeutics, Inc.

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - May 11th, 2026 7:51 am
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update - May 11th, 2026 5:00 am
3 US Biotechs Developing Parkinson’s Therapies - May 4th, 2026 9:51 pm
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 - Apr 24th, 2026 6:30 am
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update - Mar 26th, 2026 5:00 am
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference - Mar 24th, 2026 2:34 pm
Gain Therapeutics to Present at the 38th Annual ROTH Conference - Mar 19th, 2026 2:57 pm
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 - Mar 18th, 2026 6:15 am
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - Mar 12th, 2026 5:00 am
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 19th, 2026 5:00 am
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - Jan 7th, 2026 5:00 am
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - Jan 6th, 2026 5:00 am
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Dec 22nd, 2025 10:00 am
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - Dec 18th, 2025 2:05 pm
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease - Dec 18th, 2025 5:00 am
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - Dec 8th, 2025 10:00 am
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development - Nov 28th, 2025 11:26 pm
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - Nov 20th, 2025 5:00 am
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - Nov 17th, 2025 10:00 am
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - Nov 12th, 2025 5:00 am